Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11), Zacks reports. During the same period in the previous year, the company posted ($0.84) earnings per share.

Xenon Pharmaceuticals Stock Up 0.8%

Shares of XENE stock traded up $0.34 during trading on Thursday, reaching $44.92. The company’s stock had a trading volume of 709,123 shares, compared to its average volume of 917,995. Xenon Pharmaceuticals has a one year low of $26.74 and a one year high of $46.60. The business has a fifty day moving average price of $42.51 and a 200-day moving average price of $40.94. The company has a market cap of $3.47 billion, a price-to-earnings ratio of -11.55 and a beta of 0.96.

Analysts Set New Price Targets

XENE has been the topic of a number of research analyst reports. Royal Bank Of Canada raised their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Wells Fargo & Company increased their target price on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an “overweight” rating in a research note on Thursday, December 11th. Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $55.17.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the sale, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 65,302 shares of company stock valued at $2,924,128 over the last ninety days. 4.07% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals in the third quarter valued at about $32,000. Kestra Advisory Services LLC acquired a new position in Xenon Pharmaceuticals during the fourth quarter valued at approximately $33,000. Osaic Holdings Inc. grew its stake in Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $43,000. Finally, State of Wyoming raised its stake in shares of Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 350 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.